APP
APTO

Alpha Paradigm Partners’s Aptose Biosciences, Inc. APTO Stock Holding History

Alpha Paradigm Partners’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-154
Closed -$303K – 670
2020
Q4 		$303K Buy
+154
New +$362K 0.1% 218

Other funds holding APTO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Alpha Paradigm Partners's APTO Position: Q1 2021 in Review

Alpha Paradigm Partners sold out of Aptose Biosciences, Inc. (APTO) in Q1 2021, closing a stake of 154 shares — an estimated $303K sold.

Alpha Paradigm Partners first reported a position in APTO in Q4 2020 and held it in 1 quarter. The position peaked at $303K in Q4 2020. 70 funds tracked by Wall St. Rank hold APTO as of Q1 2021.

  • Alpha Paradigm Partners reported no remaining Aptose Biosciences, Inc. position as of Q1 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 154 Aptose Biosciences, Inc. shares in Q1 2021, an estimated $303K.
  • Alpha Paradigm Partners first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 1 quarter.
  • Alpha Paradigm Partners's Aptose Biosciences, Inc. position peaked at $303K in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2021.

Based on Alpha Paradigm Partners's 13F filing for Q1 2021, filed 14 May 2021.